Third Harmonic Bio, Inc.
THRD
Cena:
Valuace
70
Růst
45
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
THIRD HARMONIC BIO ANNOUNCES STOCKHOLDER APPROVAL OF PLAN OF LIQUIDATION AND DISSOLUTION, UPDATED THB335 PHASE 1 CLINICAL DATA, AND INITIATION OF SALE OF THB335
12-06-2025
STOCKHOLDERS OVERWHELMINGLY APPROVED LIQUIDATION AND DISSOLUTION OF THE COMPANY AT THE JUNE 5, 2025 ...
Více zde
THIRD HARMONIC BIO ANNOUNCES PLAN OF LIQUIDATION AND DISSOLUTION
14-04-2025
BOARD OF DIRECTORS HAS APPROVED PLAN TO LIQUIDATE AND INTENDS TO SEEK STOCKHOLDER APPROVAL FOR DISSO...
Více zde
THIRD HARMONIC BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
27-03-2025
RECENTLY PRESENTED THB335 PHASE 1 DATA SUPPORT ADVANCEMENT INTO PHASE 2 CLINICAL TRIAL IN CHRONIC SP...
Více zde
THIRD HARMONIC BIO ANNOUNCES PHASE 1 CLINICAL RESULTS FOR THB335 AND PROVIDES CORPORATE STRATEGIC UPDATE
11-02-2025
THB335 PHASE 1 DATA SUPPORT ADVANCEMENT INTO PHASE 2 CLINICAL TRIAL IN CHRONIC SPONTANEOUS URTICAR...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN THE 7TH ANNUAL EVERCORE HEALTHCONX CONFERENCE
25-11-2024
SAN FRANCISCO, NOV. 25, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLINICAL...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN NOVEMBER
07-11-2024
SAN FRANCISCO, NOV. 07, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLINICAL...
Více zde
THIRD HARMONIC BIO ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS
07-11-2024
THB335 PHASE 1 SAD/MAD CLINICAL TRIAL ON TRACK TO DELIVER CLINICAL RESULTS IN 1Q'25 STRONG FINANCIAL...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN SEPTEMBER
10-09-2024
SAN FRANCISCO, SEPT. 10, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLINICA...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
26-08-2024
SAN FRANCISCO, AUG. 26, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLINICAL...
Více zde
THIRD HARMONIC BIO ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
08-08-2024
THB335 PHASE 1 SAD/MAD CLINICAL TRIAL PROGRESSING; STUDY NOW ON TRACK TO REPORT CLINICAL RESULTS IN ...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
28-05-2024
SAN FRANCISCO, MAY 28, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLINICAL-...
Více zde
THIRD HARMONIC BIO ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
15-05-2024
U.S. FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR THB335 PHASE 1 SAD/MAD CLINICAL TRIAL INITI...
Více zde
THIRD HARMONIC BIO APPOINTS GEOFF MCDONOUGH, M.D., TO ITS BOARD OF DIRECTORS
28-03-2024
SAN FRANCISCO, MARCH 28, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A BIOPHAR...
Více zde
THIRD HARMONIC BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
26-03-2024
U.S. IND FILED FOR THB335 WITH ANTICIPATED CLINICAL TRIAL START DURING 2Q'24 STRONG FINANCIAL POSITI...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
26-02-2024
SAN FRANCISCO, FEB. 26, 2024 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A BIOPHARM...
Více zde
SHAREHOLDER ALERT: PURCELL & LEFKOWITZ LLP ANNOUNCES SHAREHOLDER INVESTIGATION OF THIRD HARMONIC BIO, INC. (NASDAQ: THRD)
22-02-2024
NEW YORK , FEB. 22, 2024 /PRNEWSWIRE/ -- PURCELL & LEFKOWITZ LLP ANNOUNCES THAT IT IS INVESTIGATING...
Více zde
THIRD HARMONIC BIO APPOINTS CHRISTOPHER MURPHY AS CHIEF FINANCIAL AND BUSINESS OFFICER AND PROVIDES BUSINESS UPDATE
04-01-2024
CHRIS BRINGS EXTENSIVE ENTERPRISE-LEVEL LEADERSHIP EXPERIENCE IN BUSINESS DEVELOPMENT, COMMERCIAL OP...
Více zde
SHAREHOLDER ALERT: PURCELL & LEFKOWITZ LLP ANNOUNCES SHAREHOLDER INVESTIGATION OF THIRD HARMONIC BIO, INC. (NASDAQ: THRD)
09-11-2023
NEW YORK , NOV. 9, 2023 /PRNEWSWIRE/ -- PURCELL & LEFKOWITZ LLP ANNOUNCES THAT IT IS INVESTIGATING ...
Více zde
THIRD HARMONIC BIO ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS
09-11-2023
ON TRACK TO FILE A U.S. INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR THB335 AND INITIATE CLINICA...
Více zde
THIRD HARMONIC BIO ANNOUNCES LEADERSHIP CHANGES
31-10-2023
SAN FRANCISCO, OCT. 31, 2023 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A BIOPHARM...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
31-08-2023
SAN FRANCISCO, AUG. 31, 2023 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A BIOPHARM...
Více zde
THIRD HARMONIC BIO ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS
10-08-2023
INTRODUCED NEXT-GENERATION ORAL KIT INHIBITOR PRODUCT CANDIDATE THB335, WHICH RETAINS THE POTENCY AN...
Více zde
SHAREHOLDER ALERT: PURCELL & LEFKOWITZ LLP IS INVESTIGATING THIRD HARMONIC BIO, INC. FOR POTENTIAL BREACHES OF FIDUCIARY DUTY BY ITS BOARD OF DIRECTORS
01-08-2023
NEW YORK , AUG. 1, 2023 /PRNEWSWIRE/ -- PURCELL & LEFKOWITZ LLP, A CLASS ACTION LAW FIRM DEDICATED T...
Více zde
THIRD HARMONIC BIO ANNOUNCES NEXT-GENERATION ORAL KIT INHIBITOR PRODUCT CANDIDATE THB335
25-07-2023
THB335 RETAINS SELECTIVITY AND POTENCY OF FIRST-GENERATION ORAL KIT INHIBITOR, THB001, WITH DIFFEREN...
Více zde
THIRD HARMONIC BIO ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS
11-05-2023
COMPANY PROGRESSES PRECLINICAL NEXT-GENERATION ORAL KIT INHIBITOR FOR MAST CELL-MEDIATED INFLAMMATOR...
Více zde
THIRD HARMONIC BIO ANNOUNCES FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS
29-03-2023
COMPANY PROGRESSES PRECLINICAL NEXT-GENERATION ORAL KIT INHIBITOR FOR MAST CELL-MEDIATED INFLAMMATOR...
Více zde
THIRD HARMONIC BIO ANNOUNCES DISCONTINUATION OF PHASE 1B STUDY OF THB001 IN CHRONIC INDUCIBLE URTICARIA
15-12-2022
-- COMPANY DECISION FOLLOWS OBSERVATION OF ASYMPTOMATIC LIVER TRANSAMINITIS IN TWO SUBJECTS ENROLLED...
Více zde
THIRD HARMONIC BIO TO PARTICIPATE IN FIRESIDE CHAT AT THE EVERCORE ISI 5TH ANNUAL HEALTHCONX CONFERENCE
21-11-2022
CAMBRIDGE, MASS., NOV. 21, 2022 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLINI...
Více zde
THIRD HARMONIC BIO ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
09-11-2022
SUCCESSFULLY COMPLETED UPSIZED INITIAL PUBLIC OFFERING PROVIDING FUNDING THROUGH 2025...
Více zde
THIRD HARMONIC BIO ANNOUNCES CLOSING OF UPSIZED INITIAL PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
19-09-2022
CAMBRIDGE, MASS., SEPT. 19, 2022 (GLOBE NEWSWIRE) -- THIRD HARMONIC BIO, INC. (NASDAQ: THRD), A CLIN...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2025-07-31 01:00:00 | 8-K |  | Stáhnout |
| 2025-07-31 00:00:00 | 8-K | | Stáhnout |
| 2025-07-21 01:00:00 | 8-K | | Stáhnout |
| 2025-07-21 00:00:00 | 8-K | | Stáhnout |
| 2025-06-12 01:00:00 | 8-K | | Stáhnout |
| 2025-06-12 00:00:00 | 8-K | | Stáhnout |
| 2025-06-11 01:00:00 | 8-K | | Stáhnout |
| 2025-06-11 00:00:00 | 8-K | | Stáhnout |
| 2025-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2025-04-22 01:00:00 | 8-K | | Stáhnout |
| 2025-04-22 00:00:00 | 8-K | | Stáhnout |
| 2025-04-14 01:00:00 | 8-K | | Stáhnout |
| 2025-04-14 00:00:00 | 8-K | | Stáhnout |
| 2025-03-27 00:00:00 | 8-K | | Stáhnout |
| 2025-03-27 00:00:00 | 10-K | | Stáhnout |
| 2025-03-26 23:00:00 | 8-K | | Stáhnout |
| 2025-03-26 23:00:00 | 10-K | | Stáhnout |
| 2025-03-11 00:00:00 | 8-K | | Stáhnout |
| 2025-03-10 23:00:00 | 8-K | | Stáhnout |
| 2025-02-11 00:00:00 | 8-K | | Stáhnout |
| 2025-02-10 23:00:00 | 8-K | | Stáhnout |
| 2024-11-07 00:00:00 | 8-K | | Stáhnout |
| 2024-11-07 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-06 23:00:00 | 8-K | | Stáhnout |
| 2024-11-06 23:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 01:00:00 | 8-K | | Stáhnout |
| 2024-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 00:00:00 | 8-K | | Stáhnout |
| 2024-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-06-07 01:00:00 | 8-K | | Stáhnout |
| 2024-06-07 00:00:00 | 8-K | | Stáhnout |
| 2024-05-15 01:00:00 | 8-K | | Stáhnout |
| 2024-05-15 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-15 00:00:00 | 8-K | | Stáhnout |
| 2024-05-15 00:00:00 | 10-Q | | Stáhnout |
| 2024-03-28 00:00:00 | 8-K | | Stáhnout |
| 2024-03-27 23:00:00 | 8-K | | Stáhnout |
| 2024-03-26 00:00:00 | 8-K | | Stáhnout |
| 2024-03-26 00:00:00 | 10-K | | Stáhnout |
| 2024-03-25 23:00:00 | 8-K | | Stáhnout |
| 2024-03-25 23:00:00 | 10-K | | Stáhnout |
| 2024-01-04 00:00:00 | 8-K | | Stáhnout |
| 2024-01-03 23:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-08 23:00:00 | 8-K | | Stáhnout |
| 2023-11-08 23:00:00 | 10-Q | | Stáhnout |
| 2023-10-31 00:00:00 | 8-K | | Stáhnout |
| 2023-10-30 23:00:00 | 8-K | | Stáhnout |
| 2023-08-10 01:00:00 | 8-K | | Stáhnout |
| 2023-08-10 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-10 00:00:00 | 8-K | | Stáhnout |
| 2023-08-10 00:00:00 | 10-Q | | Stáhnout |
| 2023-07-25 01:00:00 | 8-K | | Stáhnout |
| 2023-07-25 00:00:00 | 8-K | | Stáhnout |
| 2023-06-08 01:00:00 | 8-K | | Stáhnout |
| 2023-06-08 00:00:00 | 8-K | | Stáhnout |
| 2023-05-11 01:00:00 | 8-K | | Stáhnout |
| 2023-05-11 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-11 00:00:00 | 8-K | | Stáhnout |
| 2023-05-11 00:00:00 | 10-Q | | Stáhnout |
| 2023-03-29 01:00:00 | 8-K | | Stáhnout |
| 2023-03-29 01:00:00 | 10-K | | Stáhnout |
| 2023-03-29 00:00:00 | 8-K | | Stáhnout |
| 2023-03-29 00:00:00 | 10-K | | Stáhnout |
| 2023-03-08 00:00:00 | 8-K | | Stáhnout |
| 2023-03-07 23:00:00 | 8-K | | Stáhnout |
| 2023-01-19 00:00:00 | 8-K | | Stáhnout |
| 2023-01-18 23:00:00 | 8-K | | Stáhnout |
| 2022-12-21 00:00:00 | 8-K | | Stáhnout |
| 2022-12-20 23:00:00 | 8-K | | Stáhnout |
| 2022-11-09 00:00:00 | 8-K | | Stáhnout |
| 2022-11-09 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-08 23:00:00 | 8-K | | Stáhnout |
| 2022-11-08 23:00:00 | 10-Q | | Stáhnout |
| 2022-10-25 01:00:00 | 8-K | | Stáhnout |
| 2022-10-25 00:00:00 | 8-K | | Stáhnout |
| 2022-10-11 01:00:00 | 8-K | | Stáhnout |
| 2022-10-11 00:00:00 | 8-K | | Stáhnout |
